CN103446114A - Applications of Sarcaboside A in antibacterial medicament - Google Patents
Applications of Sarcaboside A in antibacterial medicament Download PDFInfo
- Publication number
- CN103446114A CN103446114A CN201310430764XA CN201310430764A CN103446114A CN 103446114 A CN103446114 A CN 103446114A CN 201310430764X A CN201310430764X A CN 201310430764XA CN 201310430764 A CN201310430764 A CN 201310430764A CN 103446114 A CN103446114 A CN 103446114A
- Authority
- CN
- China
- Prior art keywords
- sarcaboside
- applications
- antibacterial
- preparing
- belongs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to applications of Sarcaboside A in preparing an antibacterial medicament, and belongs to the field of medicines. The Sarcaboside A plays a strong role in inhibiting escherichia coli, pseudomonas fluorescens, staphylococcus aureus, proteus and cryptococcus neoformans, thus being capable of serving as an antibacterial compound, and being expected to be applied in preparing related medicaments. The applications of the Sarcaboside A in preparing the antibacterial medicament are disclosed for the first time. As a skeleton type of the Sarcaboside A belongs to a brand-new skeleton type, the Sarcaboside A has unexpectedly strong bacteria inhibition activity, and the possibility of giving any inspiration by other compounds does not exist. The Sarcaboside A has significantly substantive characteristics, as well as obviously prominent progress in the prevention and treatment of the bacteria infection.
Description
Technical field
The present invention relates to the purposes of Sarcaboside A, relate in particular to the application of Sarcaboside A in preparing anti-bacterial drug.
Background technology
The mankind's health and lives in the enhancing serious threat of the diffusion of pathogenic bacterium and drug resistance thereof, antibacterials are widely used in acquired immune deficiency syndrome (AIDS) as routine administration, organ transplantation and Chronic consumptions are (as cancer, diabetes, uremia etc.) treatment, although the antimicrobial agent of using clinically at present is (as ketoconazole, amikacin, gentamycin, voriconazole, itraconazole, terbinafine, amphotericin, fluconazol etc.) better to the curative effect of skin and superficial place infection, but the cumulative toxicity of these antibacterials is stronger, usually cause lesions of liver and kidney, digestive tract stimulates, dizzy, irritated etc., become one of focus of current medicament research and development so find the novel antibacterial medicine of mechanism of action uniqueness.
The compound S arcaboside A the present invention relates to is one and within 2012, delivers (Li, X.et al., 2012.Two New-Skeleton Compounds from Sarcandra glabra.Helvetica Chimica Acta95 (6), 998-1002.) New skeleton compound, this compound has brand-new framework types, at present not about active report, belong to open first for the purposes of Sarcaboside A in preparing anti-bacterial drug the present invention relates to, because framework types belongs to brand-new framework types, and it is active unexpectedly strong for bacteriostatic, there do not is the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, the control of simultaneously infecting for antibacterial obviously has significant progress.
Summary of the invention
The object of the invention is to:
The application of a kind of Sarcaboside A of the present invention in preparing anti-bacterial drug is provided.
Described compound S arcaboside A structure is as shown in formula I:
Sarcaboside A has the effect of very strong inhibition escherichia coli, fluorescent pseudomonas, Staphylococcus aureus, Bacillus proteus, neogenesis cryptococcus, so Sarcaboside A can be used as the compound with antibacterial action, and be expected to be applied in the preparation antibacterials.
It is open first that the purposes of Sarcaboside A in preparing anti-bacterial drug belongs to, because framework types belongs to brand-new framework types, and it is active unexpectedly strong for bacteriostatic, there do not is the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control of simultaneously infecting for antibacterial obviously has significant progress.
The specific embodiment
The preparation method of compound S arcaboside A involved in the present invention is referring to document (Li, X.et al., 2012.Two New-Skeleton Compounds from Sarcandra glabra.Helvetica Chimica Acta95 (6), 998-1002.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound S arcaboside A tablet involved in the present invention:
Get 20 and digest compound Sarcaboside A, add conventional adjuvant 180 grams that prepare tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound S arcaboside A capsule involved in the present invention:
Get 20 and digest compound Sarcaboside A, add the conventional adjuvant for preparing capsule as starch 180 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: Sarcaboside A antibacterial activity
Antibacterial activity test is the method that adopts concentration dilution, measures triplicate at every turn, and the test pathogen has escherichia coli, fluorescent pseudomonas, Staphylococcus aureus, Bacillus proteus, neogenesis cryptococcus, and bacterial concentration is 10
5individual/mL.The SarcabosideA initial concentration is 50.0 μ g/mL(5% dimethyl sulfoxide DMSO), gradient dilution to 0.098 μ g/mL, the bacterium liquid of equivalent volumes and specimen Mixed culture are in 96 orifice plates, the antibacterial culturing temperature is respectively 37 ℃, after incubation time 24h, observe, if discovery is the sample lowest concentration of antimicrobial while not having bacterium colony to form, i.e. the MIC value.This experiment positive control is amikacin sulfate, and Sarcaboside A the anti-bacterial result is in Table 1.
The table antibiotic MIC value of 1Sarcaboside A (μ g/mL)
Conclusion: Sarcaboside A has very strong antibacterial activity, and therefore Sarcaboside A of the present invention is expected to be used to prepare the novel antibacterial medicine.
Claims (1)
1.Sarcaboside the application of A in anti-bacterial drug, described compound S arcaboside A structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310430764XA CN103446114A (en) | 2013-09-18 | 2013-09-18 | Applications of Sarcaboside A in antibacterial medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310430764XA CN103446114A (en) | 2013-09-18 | 2013-09-18 | Applications of Sarcaboside A in antibacterial medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103446114A true CN103446114A (en) | 2013-12-18 |
Family
ID=49729236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310430764XA Pending CN103446114A (en) | 2013-09-18 | 2013-09-18 | Applications of Sarcaboside A in antibacterial medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103446114A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106188212A (en) * | 2014-06-25 | 2016-12-07 | 虞定生 | The application in antibacterials of Cleistanone derivant and pharmaceutically acceptable salt |
-
2013
- 2013-09-18 CN CN201310430764XA patent/CN103446114A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106188212A (en) * | 2014-06-25 | 2016-12-07 | 虞定生 | The application in antibacterials of Cleistanone derivant and pharmaceutically acceptable salt |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103251611A (en) | Application of Aspeverin in preparation of anti-bacteria medicines | |
| CN103462968B (en) | Incarviatone A is preparing the application in anti-bacterial drug | |
| CN102872105B (en) | Application of Houttuynoid C in antibacterial medicine | |
| CN102861076B (en) | Application of Houttuynoid A in antibacterial medicine | |
| CN103446125B (en) | Lycojaponicumin B is preparing the application in anti-bacterial drug | |
| CN103446114A (en) | Applications of Sarcaboside A in antibacterial medicament | |
| CN102872090B (en) | Application of Houttuynoid D in anti-bacterial agents | |
| CN102872030B (en) | Application of Gypensapogenin B in antibacterial drugs | |
| CN102895238B (en) | Application of Gypensapogenin A in antibacterial medicament | |
| CN103463037B (en) | Lycojaponicumin A is preparing the application in anti-bacterial drug | |
| CN103381164B (en) | Chukrasone A is preparing the application in anti-bacterial drug | |
| CN103381153B (en) | Chukrasone B is preparing the application in anti-bacterial drug | |
| CN103463075B (en) | Lycojaponicumin C is preparing the application in anti-bacterial drug | |
| CN103446106A (en) | Applications of Sarcaboside B in antibacterial medicament | |
| CN103027907A (en) | Application of Aphanamixoid A in preparation of antibacterial drugs | |
| CN103356517B (en) | Application of Scopariusins in preparation of antibacterial medicines | |
| CN102872146A (en) | Application of Houttuynoid D in antibacterial drugs | |
| CN102895251A (en) | Application of Houttuynoid E in antibacterial drugs | |
| CN103638010B (en) | Application of Artoxanthochromane in antibacterial drugs | |
| CN103462982B (en) | Spirooliganones B is preparing the application in anti-bacterial drug | |
| CN103446115A (en) | Applications of Sarcaboside A in medicament against human fungus | |
| CN105412091A (en) | Application of Daphnilongeranine C in preparing antibacterial drugs | |
| CN103127067A (en) | Application of Eryngiolide A in antibacterial medicines | |
| CN102861087B (en) | Application of Houttuynoid D in anti-human fungi medicine | |
| CN103462989A (en) | Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131218 |